|
|
Volumn 54, Issue 12, 2015, Pages 1297-1298
|
|
Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”
a
a
Galapagos SASU
(France)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CARBOXYLESTERASE;
CARBOXYLESTERASE 1;
FILGOTINIB;
JANUS KINASE 1;
UNCLASSIFIED DRUG;
ANTIRHEUMATIC AGENT;
PYRIDINE DERIVATIVE;
TRIAZOLE DERIVATIVE;
DRUG METABOLISM;
ENZYME INHIBITION;
FIRST PASS EFFECT;
HUMAN;
LETTER;
MAXIMUM PLASMA CONCENTRATION;
METABOLITE;
PHARMACODYNAMICS;
PHASE 2 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
ARTHRITIS, RHEUMATOID;
MALE;
METABOLISM;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
HUMANS;
MALE;
PYRIDINES;
TRIAZOLES;
|
|
EID: 84948578810
PISSN: 03125963
EISSN: 11791926
Source Type: Journal
DOI: 10.1007/s40262-015-0336-5 Document Type: Letter |
|
Times cited : (8)
|
|
References (1)
|
